Video

Urology Times 50 Innovations Series: Stem cell–derived therapy for stress urinary incontinence

Author(s):

Urology Times staff

"The newest frontier of therapy for stress incontinence is regenerative medicine and stem cell–based therapies," says Melissa R. Kaufman, MD, PhD, FACS.

Urology Times is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Melissa R. Kaufman, MD, PhD, FACS, discusses the innovative use of stem cell–derived treatments in urologic conditions such as stress urinary incontinence. . Dr. Kaufman is a Professor of urology, Patricia and Rodes Hart Endowed Chair of Urologic Surgery, and Chief of Reconstructive Urology and Pelvic Health at Vanderbilt University Medical Center, Nashville, Tennessee.

Related Videos
Andrew C. Peterson, MD, MPH, answers a question during a Zoom interview
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
Andrew C. Peterson, MD, MPH, answers a question during a Zoom video interview
Akhil Das, MD, FACS, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Elisabeth M. Sebesta, MD, answers a question during a Zoom video interview
Jacqueline Zillioux, MD, answers a question during a Zoom video interview
Related Content
FDA greenlights pivotal trial of wearable bioelectronic device for OAB
December 12th 2024

FDA greenlights pivotal trial of wearable bioelectronic device for OAB

Hannah Clarke
The primary aims for the EVANESCE-II trial are to confirm the safety of the FemPulse System and to establish noninferiority to first-line tolterodine.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
OASIS: Efficacy of Revi System for urgency incontinence maintained at 2 years
October 25th 2024

OASIS: Efficacy of Revi System for urgency incontinence maintained at 2 years

Hannah Clarke
The therapeutic response rate was 79% at 24 months, which is comparable to the rates seen at 6 months (78%) and 12 months (82%).
Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff
“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
Pelvic floor yoga is not superior to general physical conditioning for urinary incontinence
August 28th 2024

Pelvic floor yoga is not superior to general physical conditioning for urinary incontinence

Hannah Clarke
Over 12 weeks, the average reduction in total UI frequency was 2.3 episodes per day among those in the pelvic yoga program compared with 1.9 episodes per day among those in the general physical conditioning program.
Increasing thiazide doses linked to fewer kidney stone events
August 27th 2024

Increasing thiazide doses linked to fewer kidney stone events

Hannah Clarke
“What this means for patients is that thiazides remain an important option in the toolkit for preventing kidney stone recurrence,” says Ryan S. Hsi, MD, FACS.
© 2024 MJH Life Sciences

All rights reserved.